MFG
VNDA icon

Merit Financial Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Merit Financial Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
26,167
+15,001
+134% +$98K ﹤0.01% 2159
2026
Q1 		$77.2K Buy
+11,166
New +$86.1K ﹤0.01% 2035

Other funds holding VNDA

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
CAL
Capital Advisors Ltd Shaker Heights, Ohio $991M AUM 19.82% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Merit Financial Group's VNDA Position: Q2 2026 in Review

Merit Financial Group increased its Vanda Pharmaceuticals (VNDA) stake by 134% in Q2 2026, buying an estimated $98K and bringing the position to 26,167 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #2159.

Merit Financial Group first reported a position in VNDA in Q1 2026 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Merit Financial Group held 26,167 shares of Vanda Pharmaceuticals worth $160K as of Q2 2026.
  • Merit Financial Group bought 15,001 Vanda Pharmaceuticals shares in Q2 2026, an estimated $98K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2159 holding.
  • Merit Financial Group first reported a position in Vanda Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.